Literature DB >> 31846293

A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens.

Zhenzhen Zi1, Yajie Zhang1, Peng Zhang2,3, Qing Ding1, Michael Chu1, Yiwen Chen2, John D Minna4, Yonghao Yu1.   

Abstract

A powerful means to understand the cellular function of corrupt oncogenic signaling programs requires perturbing the system and monitoring the downstream consequences. Here, using a unique pair of non-small cell lung cancer (NSCLC)/normal lung epithelial patient-derived cell lines (HCC4017/HBEC30KT), we systematically interrogated the remodeling of the NSCLC proteome upon treatment with 35 chemical perturbagens targeting a diverse array of mechanistic classes. HCC4017 and HBEC30KT cells differ significantly in their proteomic response to the same compound treatment. Using protein covariance analyses, we identified a large number of functional protein networks. For example, we found that a poorly studied protein, C5orf22, is a novel component of the WBP11/PQBP1 splicing complex. Depletion of C5orf22 leads to the aberrant splicing and expression of genes involved in cell growth and immunomodulation. In summary, we show that by systematically measuring the tumor adaptive responses at the proteomic level, an understanding could be generated that provides critical circuit-level biological insights for these pharmacologic perturbagens.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31846293      PMCID: PMC7268550          DOI: 10.1021/acschembio.9b00694

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  40 in total

Review 1.  MCM proteins in DNA replication.

Authors:  B K Tye
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 2.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

Review 3.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.

Authors:  Arjan Gower; Yisong Wang; Giuseppe Giaccone
Journal:  J Mol Med (Berl)       Date:  2014-05-23       Impact factor: 4.599

Review 4.  The Mcm complex: unwinding the mechanism of a replicative helicase.

Authors:  Matthew L Bochman; Anthony Schwacha
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

5.  The Ndc80 kinetochore complex directly modulates microtubule dynamics.

Authors:  Neil T Umbreit; Daniel R Gestaut; Jerry F Tien; Breanna S Vollmar; Tamir Gonen; Charles L Asbury; Trisha N Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

6.  A Proteomic Connectivity Map.

Authors:  Christian Feller; Ruedi Aebersold
Journal:  Cell Syst       Date:  2018-04-25       Impact factor: 10.304

Review 7.  Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Authors:  Erin L Stewart; Samuel Zhixing Tan; Geoffrey Liu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2015-02

8.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582

Review 9.  Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?

Authors:  T J Mitchison; J Pineda; J Shi; S Florian
Journal:  Open Biol       Date:  2017-11       Impact factor: 6.411

10.  Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice.

Authors:  Jaemin Lee; Junli Liu; Xudong Feng; Mario Andrés Salazar Hernández; Patrick Mucka; Dorina Ibi; Jae Won Choi; Umut Ozcan
Journal:  Nat Med       Date:  2016-08-01       Impact factor: 53.440

View more
  1 in total

1.  Quantitative phosphoproteomic analyses identify STK11IP as a lysosome-specific substrate of mTORC1 that regulates lysosomal acidification.

Authors:  Zhenzhen Zi; Zhuzhen Zhang; Qiang Feng; Chiho Kim; Xu-Dong Wang; Philipp E Scherer; Jinming Gao; Beth Levine; Yonghao Yu
Journal:  Nat Commun       Date:  2022-04-01       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.